Wugen Selected for US FDA CMC Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel April 15, 2026
Opdivo combination regimens received FDA approval for previously untreated, Stage III or IV cHL and EC approval in R/R cHL after one prior line of therapy March 24, 2026
Tazverik® (tazemetostat) voluntarily withdrawn in follicular lymphoma and epithelioid sarcoma March 17, 2026
Type A meeting with FDA scheduled to discuss the CRL to the BLA for tabelecleucel (tab-cel) March 17, 2026
FDA approves IND application for GNTbm-38 for Ph 1 trial in Advanced Solid Tumors and R/R PTCL March 10, 2026
First patient dosed in the PiNACLE – H2H Ph 3 trial of rondecabtagene autoleucel (ronde-cel or LYL314) vs liso-cel or axi-cel in 2L R/R LBCL February 17, 2026
FDA Approves Label Update for Yescarta for R/R Primary Central Nervous System Lymphoma February 9, 2026
FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma February 1, 2026
Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Ph 3 EPCORE® DLBCL-1 Trial in Patients with R/R DLBCL Announced January 18, 2026
Durable Complete Response of 15 Months with a Chemo-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma Announced January 18, 2026
Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) in 1L DLBCL Announced January 11, 2026
IND application submitted to FDA for ALA-101 allogeneic CAR-iNKT cell therapy targeting CD19-positive NHL and leukemias January 4, 2026
Enrollment progress update provided on Ph 3 TERZO study of COPIKTRA (duvelisib) in adults with R/R nodal TFHL December 30, 2025
Japan’s MHLW approves Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with 2L+ FL December 30, 2025
NCCN® Duvelisib (COPIKTRA®) Update to Clinical Practice Guidelines in Oncology for CTCL December 22, 2025
FDA Grants Priority Review to supplemental BLA for Opdivo® + Chemo Combo for Classical Hodgkin Lymphoma December 15, 2025
